Illuminating the
Right Decisions for
Your Patients

Precision Medicine

 

In recent years, the treatment of cancer has shifted from a one-size-fits-all approach using chemotherapy (which kills all cells including healthy cells) to targeted therapy (which kills only cancer cells and have fewer side effects). Based on clinical studies, patients with certain genetic mutations in their tumors have been shown to respond better to specific targeted drugs. Our diagnostic tests identify clinically-relevant genetic mutations in each tumor to find the right drug for the patient. Our tests can also help to monitor treatment response and signs of cancer recurrence.

LiquidHALLMARK®

Flagship blood test that covers a wide range of clinically-relevant companion biomarkers

Learn more

HemeMARK™

In-depth genomic profiling of the hematological malignancy including myeloid and lymphoid neoplasms

Learn more

Tissue500™

Comprehensive genomic profiling of more than 500 genes in tissue specimens

Learn more

Tissue PD-L1 Triplex™

Quantitative Multiplex IHC for 3 PD-L1 clones SP142, SP263 and 22C3 in 1 tissue sample

Learn more

 

Illuminating the
Right Decisions for
Your Patients



LiquidHALLMARK®


Our flagship blood test that simultaneously detects cancer-causing gene mutations and viruses in multiple cancers to improve cancer diagnosis and treatment selection.

Cancer
Type
···
Sample
Type
···
Turnaround
Time
···
Multiple Cancers Blood 8 Days

A sensitive next-generation sequencing (NGS) liquid biopsy test covering a wide range of clinically-relevant companion biomarkers. LiquidHALLMARK® examines plasma circulating tumor DNA (ctDNA) mutations in 80 genes (available in the US starting Q3 2020 for investigational use only), including fusions in 10 genes.

Powered by AmpliMARK, Lucence’s proprietary amplicon-based NGS, LiquidHALLMARK®  supports cancer diagnosis, treatment selection, and disease monitoring. The assay identifies somatic variants in 15 cancer types, including lung, breast and colon cancers.

LiquidMARK™ tests offer cancer-specific subpanels alternatives for subsequent disease monitoring.

Download LiquidHALLMARK® and LiquidMARK™ Complete Gene List

Benefits:

  • COMPREHENSIVE
    Targets SNVs (including cis-trans), indels, CNVs, MSI, fusions, and viruses
  • SIMPLE
    Non-invasive, just 1 blood draw.
  • SENSITIVE
    Performance independently reported and validated

Recommended for patients who:

  • Require more comprehensive tumor profiling for optimal treatment selection
  • Have advanced cancers, especially when tissue biopsy is insufficient or difficult
  • Have cancers of unknown primary origin
  • Will benefit from serial monitoring of treatment outcomes

 

 

LiquidSCREEN


PCR-based blood test that detects and tracks sensitizing and resistant EGFR mutations

Cancer
Type
···
Sample
Type
···
Turnaround
Time
···
Lung Blood and
Cerebrospinal Fluid
2 Days

LiquidSCREEN™  detects specific EGFR mutations from ctDNA in the blood.
The test helps physicians select targeted therapies and monitor treatment response based on the cancer-driving mutations present.

Benefits:

  • Results ready in 2 working days for rapid decision making
  • Simple and non-invasive, only 1 blood draw
  • Ultrasensitive with detection limits of up to 0.01%

Recommended For NSCLC Patients who:

  • Have advanced or late-stage disease
  • May prefer non-invasive testing or are not suitable for invasive surgical procedure
  • Will benefit from serial monitoring of treatment outcomes
Exons Hotspot Mutations Analysed
Exon 18 G719A, G719C, G719S
Exon 19 E746_A750del, L747_P753delinsS, L747_A750delinsP, L747_T751del
Exon 20 T790M
Exon 21 L858R, L861Q

Bundled EXPRESS Service

Combined for quick and comprehensive testing

LiquidSCREEN™ Lung

1 day (instead of 2 days)

LiquidMARK™ Lung

8 days


   

HemeMARK


In-depth genomic profiling haematological malignancies including myeloid and lymphoid neoplasms.

Cancer Type
···
Sample Type
···
Turnaround Time
···
Haematological
Malignancies
Blood and Bone Marrow 10 Days

HemeMARK™ is a next-generation sequencing (NGS) based assay that detects cancer-related gene mutations from blood or bone marrow to support diagnosis, treatment selection, and disease monitoring. This NGS test detects clinically relevant mutations in various types of hematological malignancies including leukemia, lymphoma, and myeloma. This test is based on Lucence’s core molecular watermarking technology AmpliMARK™.

Download HemeMARK™ Gene List 

Tissue500


A comprehensive test panel that analyses more than 500 genes

Cancer Type
···
Sample Type
···
Turnaround Time
···
All solid tumors FFPE Tumor Tissue 4 Weeks

Tissue500™ is a comprehensive genomic profiling test that detects clinically-relevant genomic alterations in more than 500 genes to identify suitable target therapies for personalized medicine. It is able to detect multiple classes of genomic alterations and provide the status of microsatellite instability and tumor mutational burden. Broad molecular profiling picks up unanticipated and rare driver mutations, defining individual tumors to inform physicians of unique genomic signatures for personalized medicine.

Download Tissue500™ Gene List 

Benefits:

  • Analyses more than 500 genes for SNV and indel detection and 55 genes for fusion and splice variants detection
  • Matches patients to available FDA-approved targeted therapy and immunotherapy, or clinical trials to tailor cancer treatments
  • Provides comprehensive genomic analysis and biomarker status from limited tissue in one test
  • Covers all NCCN guideline-recommended genes in solid tumors, emerging biomarkers, and genes involved in over 1600 clinical trials

Recommended For:

  • Newly diagnosed patients
  • Recurrent and metastatic disease
  • Patients who are not responding well to current standard-of-care treatments

Tissue PD-L1 Triplex


Match patient's suitability across 3 immunotherapy drugs in 1 test.

Cancer Type
···
Sample Type
···
Turnaround Time
···
All Cancer Types FFPE Tumor Tissue 3 Weeks

The world’s first immunohistochemistry (IHC) tissue test that concurrently determines the expression of 3 clinically relevant tumor programmed death-ligand 1 (PD-L1) clones in 1 tissue sample.

Using quantitative multiplex fluorescence-IHC, Tissue PD-L1 Triplex™ determines the expression of PD-L1 clones SP142, SP263 and 22C3 in tumor cells and tumor-infiltrating immune cells which in turn, provides insights to the potential response of the patient towards immunotherapy.

IMMUNOTHERAPY MATCH
Atezolizumab Durvalumab Pembrolizumab Nivolumab
Non-Small Cell Lung Cancer (NSCLC) SP142 ≥ 50% TPS or ≥ 10% IC associated with enhanced overall survival SP263 ≥ 1% TPS – Post chemoradiation therapy (CRT) SP263 ≥50% TPS – First Line

SP263 ≥1% TPS – Second Line

22C3 ≥50% TPS – First Line

22C3 ≥1% TPS – Second Line

SP263 ≥1%, ≥5% and ≥10% TPS – Second Line
Urothelial Carcinoma SP142 ≥ 5% IC SP263 ≥25% TPS – Second Line

SP263 ≥ 25% IC – Second Line

Triple Negative Breast Cancer (TNBC) SP142 ≥ 1% IC


Need Help?